Table 1. Demographic characteristics and presentation of cancer by use of adjuvant therapy in Tayside, Scotland (n=4619).
| |
|
Patients with treatment (%) |
|
||
|---|---|---|---|---|---|
| No treatment (%) | Tamoxifen | AIs only | Mixed | No treatment vs treatment (χ2; d.f.; P-value) | |
| Numbers |
1258 (27) |
2230 (48) |
412 (9) |
719 (16) |
— |
|
Age group | |||||
| <40 | 74 (6) | 97 (4) | 1 (0) | 35 (5) | 23.9; 5; <0.0001 |
| 40–49 | 180 (14) | 328 (15) | 11 (3) | 118 (16) | — |
| 50–59 | 293 (23) | 553 (25) | 65 (16) | 174 (24) | — |
| 60–69 | 330 (26) | 486 (22) | 116 (28) | 169 (24) | — |
| 70–79 | 227 (18) | 442 (20) | 99 (24) | 128 (18) | — |
| 80+ | 151 (12) | 324 (15) | 120 (29) | 95 (13) | — |
| Unknown |
3 (1) |
0 (0) |
0 (0) |
0 (0) |
— |
|
SIMD quintile | |||||
| 1 | 137 (11) | 307(14) | 56 (13) | 90 (12) | 4.7; 4; 0.314 |
| 2 | 130(10) | 299 (14) | 61 (15) | 115 (16) | — |
| 3 | 194(15) | 362 (16) | 63 (15) | 120 (17) | — |
| 4 | 347 (28) | 722 (32) | 153 (37) | 221 (31) | — |
| 5 | 220 (18) | 500 (22) | 77 (19) | 161(22) | — |
| Unknown |
230 (18) |
40 (2) |
2 (1) |
12 (2) |
— |
|
Charlson's index | |||||
| 0–2 | 368 (29) | 650 (29) | 132 (32) | 230 (32) | 1.1; 2; 0.564 |
| 3–5 | 486 (39) | 888 (40) | 160 (39) | 277 (38) | — |
| 6+ |
404 (32) |
692 (31) |
120 (29) |
212 (30) |
— |
|
Menopausal status | |||||
| Pre | 189 (15) | 268 (12) | 5 (1) | 106 (15) | 5.2; 2; 0.073 |
| Peri | 28 (2) | 57 (3) | 4 (1) | 23 (3) | — |
| Post | 646 (52) | 914 (41) | 301 (73) | 369 (51) | — |
| Unknown |
395 (31) |
991 (44) |
102 (25) |
221 (31) |
— |
|
Tumour stage | |||||
| 1 | 235 (19) | 600(27) | 45 (11) | 147 (20) | 6.2; 3; 0.101 |
| 2 | 215 (17) | 445 (21) | 69 (17) | 138 (19) | — |
| 3 | 59 (4) | 91 (4) | 12 (3) | 34 (5) | — |
| 4 | 94 (8) | 119 (5) | 38 (9) | 92 (13) | — |
| Unknown |
655 (52) |
975 (43) |
248 (60) |
308 (43) |
— |
|
Clinical nodes | |||||
| 0 | 653 (52) | 1386 (62) | 137 (33) | 421 (59) | 11.7; 2; 0.003 |
| 1 | 147 (12) | 194 (9) | 59 (14) | 118 (16) | — |
| 2 | 41 (3) | 29(1) | 14 (4) | 21 (3) | — |
| Unknown |
417 (33) |
621 (28) |
202 (49) |
159 (22) |
— |
|
Clinical metastases | |||||
| No | 755 (60) | 1540 (69) | 162 (39) | 504 (70) | 6.9; 1; 0.008 |
| Yes | 57 (5) | 50 (2) | 17 (4) | 40 (6) | — |
| Unknown |
446 (36) |
640 (29) |
233 (57) |
175 (24) |
— |
|
Tumour grade | |||||
| 1 | 67(5) | 317 (14) | 27 (7) | 51 (7) | 266.8; 2; <0.0001 |
| 2 | 259 (21) | 827 (37) | 217 (53) | 296 (41) | — |
| 3 | 593 (47) | 502 (23) | 141 (34) | 238 (33) | — |
| Unknown |
339 (27) |
584 (26) |
27 (6) |
134 (19) |
— |
|
ER status | |||||
| Positive | 412 (33) | 1399 (63) | 382 (93) | 539 (75) | 1021.6; 1; <0.0001 |
| Negative | 564 (45) | 165 (7) | 8 (2) | 28 (4) | — |
| Unknown | 282 (22) | 666 (30) | 22 (5) | 152 (21) | — |
Abbreviations: AI=aromatase inhibitor; ER=oestrogen receptor; SIMD=Scottish Index of Multiple Deprivation.